Purpose Dual-modality PET/MR platforms add a new dimension to patient diagnosis with high resolution, functional, and anatomical imaging. The full potential of this emerging hybrid modality could be realized by using a corresponding dualmodality probe. Here, we report pegylated liposome (LP) formulations, housing a MR T 1 contrast agent (Gd) and the positron-emitting 89 Zr (half-life: 3.27 days), for simultaneous PET and MR tumor imaging capabilities. Methods
solutions. This shift in medical practice is being driven by molecular imaging tools that enable detection of disease, monitoring of personalized therapy and optimization of treatment strategy. In radiology, hybrid imaging systems such as PET/CT and SPECT/CT have revolutionized patient management, enabling high spatial resolution and sensitivity of detection overlaid with anatomically relevant information. However, CT scans provide poor soft tissue contrast and radiation exposure (1) .
The recent convergence of PET and MR platforms enables functional and anatomical data to be concurrently acquired with high sensitivity for non-invasive analysis of disease (2) . PET imaging provides in vivo quantification of the radiotracer distribution, while MR offers anatomical localization through high-resolution imaging with excellent soft-tissue contrast. Gd paramagnetic contrast agents produce positive contrast using T 1 -weighted image acquisition, and are included in nearly half of all MR studies (3, 4) . Nevertheless, the limited sensitivity of MR requires the delivery of high concentrations of paramagnetic material (5) as compared to nuclear imaging.
We hypothesized that a dual-modality paramagnetic radiopharmaceutical would be useful in realizing the full potential of this emerging hybrid modality. Namely, that a single probe carrying both a highly paramagnetic Gdpayload and a PET radionuclide could be designed using liposomal constructs. Utilization of a dual-modality probe could correct for imaging artefacts of one modality; improve delineation and characterization of metastasis in soft tissue by Gd contrast enhancement; and correct for partial volume effects in PET (6) .
For molecular imaging, liposomes (LPs) have previously incorporated long-lived gamma emitters for low-resolution and non-quantitative SPECT (7) . However, in this work PET is used to quantitatively assess targeted-LP distribution using 89 Zr for the first time. Zirconium-89 is a positronemitter with a half-life of 3.27 days (8) which is suitable for in vivo tracking of long circulating PEG 2000 -LP (Polyethylene Glycol) (9) . Herein, we describe a unique and facile chemical method to prepare simultaneous paramagnetic and radiopharmaceutical probes. Unexpectedly, an advantage of 89 Zr is that chelator-free labeling can be achieved directly on paramagnetic LPs.
LPs can also confer selective tumor-targeting following antibody (10) or peptide functionalization (11, 12) . Here we have employed octreotide (OCT), a well-characterized peptide targeting human somatostatin receptor subtype 2 (SSTr2; IC 50 02.0±0.7 nM) (13) , as a model system. This validated targeting vector enables selective accumulation of LPs; however, OCT-LP (OL) has not been quantified in vivo (9, 11, 12, 14) . SSTr2 targeted and control 89 Zr-Gd-LPs (Scheme 1) were characterized and tested in vitro and in vivo in mouse models. To our knowledge, this is the first report of a LP-based probe fusing PET and MR contrast capabilities to image neuroendocrine tumors.
MATERIALS AND METHODS

Chemicals
DSPC (1,2-disearoyl-sn-glycero-3-phosphocholine) and DSPE-PEG 2000 -OMe (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]) were purchased from Lipoid AG, Cham, Switzland; cholesterol and DSPE-PEG 2000 -CO 2 H (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxylic acid (polyethyleneglycol)-2000]) were purchased from Avanti polar Inc., Alabaster, AL, USA. Octreotide (OCT) was purchased from AnaSpec Inc., Fremont, CA. EDC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride), S-NHS (N-hydroxysulfosuccinimide); HEPES (N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid) and zirconium(IV)-chloride (Zr) were purchased from Scheme 1 LP constructs and radiolabeling strategy: OCTwas conjugated to preformed Gd-Control LPs (CL) resulting in targeted OCT-LP (OL). Both paramagnetic formulations were radiolabeled using 89 Zr with a chelator-free approach.
Sigma-Aldrich. Gd-DTPA-BiSA (Gadolinium Diethylenetriaminepentaacetic acid bis-stearylamide) was purchased from Chemir Analytical Services, Maryland Heights, MO. Desferrioxamine mesylate (DFO) was purchased from Calbiochem, Merck KGaA, Darmstadt, DE. 89 Zr was produced by irradiating an 86 Y target. The target was washed with strong acids, and the resulting solution was purified using an hydroxamate gel column eluted with oxalic acid as described by Holland et al. (15) 89 Zr[Zr]-oxalate was the radioactive source used for radiolabeling.
OCT Coupling Procedure and Analysis
OCT (1 eq.) was coupled to DSPE-PEG 2000 -CO 2 H (1 eq.) using EDC (10 eq.) and S-NHS (5 eq.), in HEPES buffer (10 mM HEPES; 150 mM NaCl adjusted to pH 6) and stirred at room temperature for 20 h. The mixture was analyzed using HPLC (Shimadzu system equipped with a UV diode array detector) and LC-ESI-QTOF MS (Waters QTof Premier). A C4-reverse phase column (Alltech Prosphere HP C4 300 Å−5 μm, 150 mm*4.6 mm) was eluted with acidified ultrapure deionized water (0.01% TFA; 0.1% NH 4 Cl) at a flow rate of 1 mL/min with an increasing linear gradient of methanol from 10 to 100% over 60 min. The column effluent was directly electrosprayed in ESI source. The mass spectrometer was set in the positive ion mode (ESI+) and acquired spectra from m/z 400 to 1500 Da at one scan rate per second (Fig. 1a, b) .
LPs Preparations
Two formulations (octreotide-liposome-OL and controlliposome-CL) constituted of DSPC/cholesterol/Gd-DTPA-BiSA/DSPE-PEG 2000 -OMe/DSPE-PEG 2000 -CO 2 H were prepared with the following ratio: 42/33/20/ 3/2. The sum of all compounds number of moles equaled 40 μmol/ animal injection. All chemicals were dissolved in a total volume of 6 mL with a dichloromethane / methanol mixture (1:1). The solution was vacuum-dried to get a thin lipidic film. The film was hydrated in HEPES buffer (pH 6), resulting in a milky suspension. Each mixture was extruded through polycarbonate membrane filters with 200 nm (ten times) and 100 nm (ten times) pores, using the Lipofast extruder (Avestin, Canada). While extruding, the temperature was maintained at 55˚C. The extruded solution was ultracentrifuged 1 h, at 4˚C, using a Beckman L7 ultracentrifuge at 266000 g. The pellet was suspended in fresh HEPES buffer pH 6 (2 mL). This suspension was split in two equal volumes of 1 mL: CL and OL. For OL, EDC (105 mM, 6 μL per animal injection) and S-NHS (50 mM, 6 μL per injection) were added 15 min prior to OCT addition (1 mM; 23 μL per injection). The conjugation was conducted overnight at 4°C with gentle shaking of the sample using a rotator. Then, OL and CL were washed and OL supernatant was HPLC analyzed to determine the amount of unbound OCT (Fig. 1d) . OL and CL pellets were both suspended in 1 mL of fresh buffer (HEPES 10 mM; NaCl 150 mM; pH 7.4). Stewart assay quantified the lipid content of each sample (16) . The average diameter and PDI of OL and CL were measured using dynamic light scattering (Malvern instrument, Westborough, Ma, USA).
Monolayer Study: Procedure and Equipment
Zr-chloride (Zr) and desferrioxamine mesylate (DFO) adsorption to lipid monolayers were tested using a Wilhelmy wire attached to a microbalance (TroughS, Kibron Inc., Helsinki, Finland) and analyzed with Delta Pi software ( Fig. 2) (17) . A well (2 cm diameter) filled with HEPES buffer pH 7.4 formed a meniscus with an air-water interface. 1 to 5 μL of DSPC dissolved in buffer (1 mg/mL) was incorporated on the meniscus to reconstitute a lipid monolayer film. Increasing DSPC addition resulted in increasing initial surface pressures (π i ). Varying π i , we examined Δπ after addition of Zr (10 mM; 20 μL) in the aqueous compartment ( Fig. 2b; 15<π LPs were incubated with the radioactive preparation either at room temperature or at 45°C for 2 h. The radiolabeled LPs were purified using size exclusion chromatography eluted with 10 μL of EDTA (50 mM) in HEPES buffer pH 7.4 (Sephadex G-25; gamma counted using Wizard 1480, Perkin Elmer, Waltham, MA, USA; Supplementary Material Fig. S1 ). The preparations for animal injection were concentrated by centrifugation (3 cycles of 1811g; 15 min; centrifuge Eppendorf-5810R) using Millipore Centriprep YM-10 Centrifugal units. A final filtration was performed to sterilize the preparations using Millipore syringe filter with 200 μm porosity.
The specific activity was calculated after LPs purification either considering the activity (μCi) per lipids (mol) after Stewart assay (16) 
Stability Study
89 Zr-CL was incubated overnight at 37°C in HEPES buffer pH 7.4 and split in three groups of wash (Millipore Centriprep YM-10).
89 Zr-CL was washed with EDTA (5 mM) or PBS (137 mM NaCl; 2.7 mM KCl; 10 mM Na 2 H-PO 4 .2H 2 O; 2 mM K 2 HPO 4 ; pH07.4) or HEPES buffer (pH07.4). In another trial, 89 Zr-CL was incubated in bovine serum albumin (BSA) (5% w/v; 100 μL; 1:1; v/v with 75 mM lipids) and mouse serum protein (MSP) (100 μL; 1:1 v/v with 75 mM lipids) at various time points (24, 48 and 96 h, n≥2) at 37°C. LPs were separated from serum proteins using Sepharose 4B gel column (Fig. 3a) . The protein content of each fractions (1 mL) was titrated using the Pierce® BCA protein assay (Pierce, Thermo Scientific). The fractions were gamma counted and these data were charted in the radioactive stability profile (Fig. 3b) .
In Vitro Evaluation
In vitro experiments were undertaken using C6 human somatostatin receptor type 2 (SSTr2-postive) transduced glioblastoma cells (21) . The cells were grown at 37°C and 5% CO 2 in DMEM supplemented with 10% fetal calf serum with 1% penicillin and streptomycin. 
Imaging Protocols and Co-registration
Animal experiments were conducted according to National Institute of Health (NIH) guidelines and the Institutional Animal Care and Use Committee of MSKCC. Female Nu/Nu NCRNU mice were subcutaneously inoculated with 1.5×10 6 cells on each shoulder with wild type (left) and 
PET Imaging
The mice were scanned 30 to 45 min on a micro-PET Focus 120 scanner (Siemens) at 4, 10, 24 and 48 h post injection (p.i.), under inhalation of 1% isoflurane (Baxter Health-care, Deerfield, IL, USA) / oxygen gas mixture (flow rate: 2 L/min) for anesthesia. PET scans were reconstructed using Concorde Microsystems software. 
MR Acquisition
MR was conducted on each animal at 24 and 50 h p.i. T 1 -weighted images were acquired on a Bruker 4.7 T 40 cm bore scanner equipped with 400 mT/m shielded gradients (Bruker Biospin MRI GmbH, Ettlingen, Germany). A 36-mm ID quadrature resonator (Stark Contrast MRI Coils Research Inc., Erlangen, Germany) was used for excitation and detection. A deionized water phantom was placed next to the mouse body as a reference for signal intensity. Initial T 2 scout images were acquired along 3 orientations for tumor localization. Axial gradient-echo images were then acquired across the xenograft tumor and the water phantom with the following acquisition parameters: TR (Repetition Time) 61 ms, TE (Echo Time) 2 ms, 1 mm slice thickness, 182 x 188 mm in-plane resolution, 16 averages. A total of 5 slices were imaged. MR co-registered 3D T1-weighted images were acquired with TR 61 ms, TE 2 ms, spatial resolution of 350 mm, and 4 averages. The tumor contrast was measured using Image J software (NIH; Bethesda, MD) looking at the grayscale intensity of group-blind region of interest (ROI) measurements. The normalized contrast enhancement was calculated by subtracting preinjection (pre) to post-injection (post) tumor over water ROI ratio (a).
Co-registration
One animal of each liposome group was submitted to CT-PET-MR co-registration. CT scans were acquired on the mouse 10 min using a microCAT II, manufactured by Imtek, Inc (Oak Ridge, TN). Accurate PET to MR registration was made possible by immobilizing the mouse on a movable PET, CT and MR compatible bed using a thin plastic wrap. The mouse was maintained in a single rigid position under isoflurane anesthesia during and between PET, CT and MR imaging sessions. Because PET and CT scanners both used calibrated bed positioning systems, the registration transformation between these two modalities could be determined a priori (23). Our MR scanner does not have a similar bed positioning capability, therefore MR to PET or MR to CT registrations require information contained within the MR images. Retrospective mutual information registration algorithms work efficiently in registering MR to CT data based on the bone visualization. Therefore, for the datasets described, we used this approach plus the a priori determined CT to PET rigid-body transform to achieve the MR to PET registration.
After imaging completion, organs and tumors were collected and gamma counted. Bones, epiphysis and the marrow were separated and gamma counted (19) .
Statistical Analysis
The statistical difference in tumor uptake was analyzed using a one-tailed unpaired student's t-test for comparing SSTr2-postive tumor uptake of OL versus CL; and, a onetailed paired student's t-test for OL SSTr2-positive and control wild type tumor.
RESULTS
Coupling of OCT to DSPE-PEG 2000 -CO 2 H and PEG 2000 -LPs
OCT was first coupled in solution to DSPE-PEG 2000 -CO 2 H using EDC and S-NHS at pH 6 to selectively react at the peptide's N-terminus (24) . The lipid-PEG 2000 -OCT conjugate was identified using mass spectrometry (Fig. 1b) . This reaction was then achieved on preformed LPs (Scheme 1) (25) . Coupling was performed without a peptide-protecting group to abrogate a potentially difficult deprotection step, which could be destructive to LPs. Coupling efficiency on LPs was 70% (Fig. 1d) , yielding targeted paramagnetic Gd-OL.
Octreotide-Liposomes (OL) and Control-Liposomes (CL) were identified with similar diameters of 115±2 nm, similar narrow polydispersity index (PDI) of 0.04±0.01 and, as previously reported, similar zeta potentials (11) . The ratio of OCT to lipid (mol/mol) in the OL preparation was calculated to be 0.001. According to the Enoch method (20), a LP of 115 nm diameter is therefore composed of 85700 lipid molecules,~40809 Gd chelates (Gd-DTPABistearylamide) molecules and~85-90 molecules of OCT.
Zr Adsorption Into DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) Membrane
The chelate desferrioxamine (DFO) has been used to radiolabel antibodies with 89 Zr (8, 26) . We discovered that this approach, in the context of a bilayered lipid particle, was plagued by interaction of the radiometal with the lipids' phosphate head groups (Fig. 2a) . This metal-lipid affinity presented the opportunity to radiolabel LP in a chelator-free strategy.
To verify this hypothesis, we tested Zr adsorption to a DSPC lipid monolayer (Fig. 2c #1) . The exponential increase in membrane surface tension (Δπ) when supplementing Zr proved its adsorption, even when the lipid compression was high (Fig. 2b) . It suggested a strong Zr affinity for the stacked lipid phosphate heads of membranes (27) .
After saturating the membrane and the aqueous compartment with Zr (Fig. 2d #2) , Zr desorption was attempted by DFO chelation. The first μmol of DFO added chelated Zr suspended in the water layer (Fig. 2d #3) resulting in no membrane interaction (Δπ00). Then, even though lipids were in excess, DFO finally desorbed Zr (Δπ <0; Fig. 2d #4) . In a different experiment (Fig. 2e) , DFO was first adsorbed onto the monolayer (#1) and it was then desorbed as a metal-complex (#4). Zr-DFO desorption showed the superior complexing power of DFO against lipids.
As discussed further, radiolabeling of LP through DFO chelation was however not the chosen strategy because of DFO strong hydrophilic affinity for the monolayer. Instead, Zr oxophilicity was exploited to radiolabel LPs membranes through phosphate affinity with lipids polar heads.
LP Radiolabeling and Stability Assays
Gd-LPs were radiolabeled using 89 Zr adsorption, and the resulting preparation was purified and tested with stability assays. No significant difference of labeling efficiency was found between OL and CL, showing the negligible effect of OCT on LP surfaces.
Radiolabeling conducted at 45˚C was more successful than that at room temperature (Supplementary Material  Fig. S1a ). At 45˚C, the efficiency approached 99% when low amounts of lipid and radioactivity were used. This efficiency decreased exponentially with increasing lipid concentration (Supplementary Material Fig. S1b ). High lipid concentration correlated with high LPs' density in solution and low radiolabeling efficiency. Moreover, the diameter and poly dispersity index of 89 Zr-LPs remained unchanged after labeling and purification. For the optimized preparation used for in vitro and in vivo studies, the specific activity was calculated to be 9.82 μCi / mg of total lipid or (5 (Fig. 3a, b) . After 24 h and up to 96 h of incubation, approximately 50% of the radioactivity remained bound to LPs at 37˚C. These results underscore that, in the absence of a chelator, 89 Zr binding to LPs is stable enough to track vesicle constructs in vitro and in vivo.
In Vitro Experiments
The affinity of 89 Zr-labeled OL for its target was tested in vitro and validated using a transduced SSTr2-positive cell line (Supplementary Material Fig. S2 ) (21) . OL showed significantly greater (p<0.05) accumulation to SSTr2 expressing cells as compared to that of CL. In addition, OL was selectively blocked through the addition of excess OCT.
Imaging and PET-MR Co-registration OL and CL were then studied using MR (Fig. 4) and PET (Fig. 5) imaging in the context of a dual-xenograft mouse model. Voxel-by-voxel analysis of MR acquisitions 50 h p.i. (Fig. 2 ) reveals contrast enhancement (mean tumor ROI of 180) for SSTr2-postive tumor as compared to that of control tumors (mean of 139). However, little tumor contrast is observed between SSTr2 and control tumors for the CL injected mouse (127 and 145, respectively) close to the baseline mean values of 126 and 123. The % contrast enhancement relative to baseline shows an approximate 2-fold increase of signal for the SSTr2-tumors of OL injected mice as compared to CL (n05), (Fig. 4c) .
PET showed that the tumor radioactivity was predominantly driven by the high blood levels up to 24 h (4 h MIP, Supplementary Material Fig. S3 ) and the tumors' permeable vasculature (28) , suggested by low tumor-to-blood ratios (Fig. 5d-24 h p.i.) . Also, no specific SSTr2 recognition was observed at 24 h with Gd and 89 Zr tracking (Supplementary Material Fig. S5a, b) . After 24 h, tumors were readily distinguishable from the blood-pool due to progressive clearance of the agent. At 50 h, OL targeting of SSTr2-positive tumors became apparent, in addition to the EPR effect (28) as seen with the autoradiography of the harvested tumors (Supplementary Material Fig. S4) .
At 50 h p.i., OL tumor uptake values in SSTr2-positive tumors (3.5-5%ID/g) were significantly greater (p<0.05) than for the control (2.5-3%ID/g). Furthermore, OL SSTr2-positive tumor uptake exceeded CL in both wild type and SSTr2 tumor uptake with~2%ID/g (Fig. 5b) .
Activity in the liver and spleen showed LP clearance through the reticular endothelial system (RES), and not dissociated free 89 Zr (9, 19) . RES uptake reached a maximum of 18% ID/g (Fig. 5b) . This is relatively low as compared to reported values of immuno-targeted LP in mice (10) .
Bone accumulation was visualized using PET throughout the study (Supplementary Material Fig. S3 ). At 4 h onlỹ 2%ID/g was observed, however bone uptake increased to 12%ID/g at later time points. No significant activity was found in the marrow, in agreement with reported studies of 89 Zr-hydroxide chloride localized in bone mineral (19) . It is likely the exchange of 89 Zr from LP to serum proteins results in a final homing of 89 Zr-colloids to bone minerals.
The greatest tumor-to-muscle and tumor-to-blood radioactive uptake ratios are seen at 50 h p.i. (Fig. 5b, c and d) ; in accordance with imaging. The tumor-to-muscle reached 25 for OL in SSTr2-positive tumor as compared to 10 and 11.5 for CL in SSTr2-and control tumors, respectively. At 96 h, CL tumor-to-blood ratio of wild type tumor equalled that of OL for SSTr2-tumors reflecting degradation of LPs over time.
At the optimum imaging time point of 50 h p.i., PET-MR imaging co-registration allowed for clear tumor identification and demonstrates SSTr2 tumor specific contrast for OL (Fig. 6) .
DISCUSSION
LPs are an established platform for drug and imaging agent delivery that exhibit low toxicity and biodegradability. In order to meet the demands of emerging multimodal hybrid Fig. 4 (a) 50 h molecular imaging, multifunctional targeted nanoparticles are proposed as single agent platforms. Herein, we described the synthesis, characterization and utility of a SSTr2-targeting LP probe housing both a PET radionuclide ( 89 Zr) and a MR contrast agent (Gd-DTPA-bistearylamide).
OCT was successfully coupled to DSPE-PEG 2000 -CO 2 H and translated to LP conjugation, without the requirement of a protecting group. The notable difference in coupling yields between OCT reacted with lipid (7%) and OCT with LPs (70%) is attributed to the OCT adsorption to membranes (as previously reported) (29) . We also observed the superior in vitro and in vivo tumor-targeting efficacy of OL in SSTr2-positive tumors over non-specific accumulation. No difference in liver and spleen uptake were observed between OL and CL, suggesting minimal peptide impact on LP surface.
The hypothesis of preformed LPs direct-labeling was first validated by observing Zr oxophilicity with lipid phosphate heads in a monolayer membrane. The radiolabeling strategy choice was influenced by the non-negligible DFO adsorption in the membranes. For instance, if a radiolabeling is conducted post DFO conjugation with LPs, it will result in 89 Zr-DFO desorption due to residual DFO adsorbed on the membranes. Consequently, this may lead to a dramatic decrease of the labeling efficiency. Instead, 89 Zr direct adsorption was chosen as a facile straightforward radiolabeling approach based on the supramolecular chemistry of 89 Zr with phospholipids.
Varying temperatures upon LP radiolabeling was informative of the radiolabeling mechanism. The high radiolabeling efficiency observed at 45˚C indicated that the membrane fluidity played a critical role in 89 Zr adsorption. Higher temperatures correlated with a greater 89 Zr exchange through membranes, facilitating the penetration of 89 Zr within membranes. The radionuclide was likely entrapped in the LPs and then interacted with the luminal phosphates heads. Moreover, the concentration of LPs when radiolabeling seems to influence the radiolabeling efficiency. Low labeling efficiency associated with high lipid concentration suggested that LPs density in solution was an important factor of radiolabeling. High LP density is linked with low membranes accessibility due to hindrance between particles and therefore a substantial decrease of adsorptive radiolabeling was observed.
Analyzing Zr-LPs radioactive stability over serum protein challenge (50% ID from 24 to 96 h).
Unfortunately, serum protein studies and radioactive bone uptake suggested in vitro and in vivo limitations of this strategy regarding the radiolabeled LPs stability. It should however be noted that throughout this study the bone radioactivity never exceeded reported values of 89 Zr-DFOmonoclonal antibodies, 6 days p.i., in mice (~15% ID/g) (8) . Furthermore, the presented LP radiolabeling method showed many advantages such as greatly simplifying the LPs formulation; reducing reaction time; and enhancing radiolabeling efficiency as well as quantitative tracking of long-circulating LPs. However, the stability of 89 Zr adsorbed LPs is debatable and an alternative LPs formulation using 89 Zr-DFO conjugate may decrease the short term bone uptake of free 89 Zr. At 50 h p.i., the multifunctional LP construct resulted in the delivery of a high Gd payload at the disease sites providing significant enhancement in tumor contrast and high resolution of images; simultaneously, 89 Zr offered quantification of LP accumulation in targeted tissues. Tumor detection using PET was, however, difficult to interpret as compared to MR due to the hindrance of bone high signals, characteristic of 89 Zr release, and liver and spleen high uptakes due to nanostructure biological fate. Nonetheless, at extended time point, 96 h p.i., LPs uptake in tumor tissue dropped to less than 2% ID/g corresponding to a Gd concentration inferior to 0.3 mM. Consequently, it involved a weaker detection of MR contrasts, as well as difficult and less accurate quantitative scans (30) . Therefore, PET and MR imaging were complementary and necessary for this study to monitor LPs.
Despite limitations, both imaging methods were in good agreement, showing a 2-fold increase of agent uptake at 50 h p.i. for OL SSTr2-positive tumor compared to CL. This observation correlates with PEG 2000 -LPs pharmacology, where the optimum tumor uptake is reported to be 48 h p.i (9) . Although non-specific EPR effect was seen, PET/ MR dual detection clearly highlighted OL tumor-specificity over CL. This proof-of-concept imaging approach may be an interesting application to translate for the tracking and quantification of clinical drug-LPs.
CONCLUSION
In conclusion, we achieved and characterized the formulation of a novel SSTr2-targeting PET/MR LP and assessed in vitro and in vivo specific SSTr2 recognition through OCT conjugated LPs. A direct 89 Zr-radiolabeling method of preformed LPs was described and its imaging applicability as a long circulating dual PET-MR tacking probe was demonstrated. Having established this methodology, other tumortargeting moieties can be associated to LPs. It is conceivable that this PET-MR LP formulation could image the biological behaviour of LP-based drugs, enabling early prediction of therapy response.
